MedTech News
.................... by Andrew Celentano
AI-aided ‘master key’ vaccine may block entire virus families, not single strains
Now, new AI-aided vaccine technology developed by scientists at Cambridge University offers potential immunity against whole families of viruses and could even prevent the next pandemic, according to researchers.
AI framework helps identify new targets for CAR T cell therapy
Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers scientists’ expertise to find viable target antigens for CAR T cell therapy.
BrightHeart secures CE mark for AI-powered prenatal ultrasound platform
This authorisation will expand the B-Right AI platform’s use to Europe, as BrightHeart continues to roll the technology out across the US.
Bandage-like device delivers hydrogen sulfide to wounds, boosting blood flow where healing stalls
Now, researchers at the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) are developing an approach that could improve healing by increasing blood flow directly at the wound site.
AI system detects sudden cardiac death risk, identifying thousands more patients annually
With a new tool that could transform how that game is played, UC Berkeley researchers have discovered a previously unrecognized signal in electrocardiograms that can better detect high-risk patients before their hearts stop.
Exposure to bright evening light linked to higher risk of age-related eye disease
Researchers found that exposure to bright artificial light in the evening, especially between 8 p.m. and 11:30 p.m., may significantly increase the risk of developing serious eye diseases later in life.
Faster Biological Aging May Help Explain Why More Younger Adults Are Getting Cancer
Younger generations are now aging faster than their parents and grandparents, and this aging gap could explain the rise in early-onset cancers.
FDA Approves Gilead’s Trodelvy, Alone and With Merck’s Keytruda, in First-Line Metastatic TNBC
Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients.